Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 680.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,537 shares of the company's stock after acquiring an additional 57,144 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Moderna were worth $6,518,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Arlington Trust Co LLC grew its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Archer Investment Corp increased its position in shares of Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company's stock worth $55,000 after acquiring an additional 222 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of Moderna by 44.9% in the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company's stock valued at $58,000 after acquiring an additional 175 shares in the last quarter. Hexagon Capital Partners LLC boosted its holdings in Moderna by 182.4% in the fourth quarter. Hexagon Capital Partners LLC now owns 610 shares of the company's stock valued at $61,000 after purchasing an additional 394 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in Moderna by 408.3% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company's stock worth $63,000 after purchasing an additional 490 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares in the company, valued at approximately $809,235.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Shannon Thyme Klinger sold 670 shares of the firm's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the sale, the insider now owns 8,557 shares in the company, valued at approximately $809,235.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company's stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders have sold 170,209 shares of company stock worth $18,588,421 in the last quarter. Company insiders own 15.70% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Oppenheimer increased their price target on Moderna from $142.00 to $163.00 and gave the company an "outperform" rating in a research report on Friday, May 3rd. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a report on Thursday, May 2nd. UBS Group raised their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a "buy" rating in a report on Tuesday, May 7th. Royal Bank of Canada lifted their price objective on shares of Moderna from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $126.46.

Moderna Stock Performance

Shares of MRNA traded up $0.22 during mid-day trading on Friday, reaching $132.90. 2,718,168 shares of the company's stock were exchanged, compared to its average volume of 3,677,185. The business's fifty day simple moving average is $110.78 and its 200-day simple moving average is $97.72. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The stock has a market capitalization of $50.93 billion, a PE ratio of -8.48 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same period last year, the firm posted $0.19 EPS. Moderna's revenue for the quarter was down 91.0% on a year-over-year basis. On average, equities research analysts expect that Moderna, Inc. will post -7.5 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.